Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas
Raphael Koch(Harvard University), David M. Weinstock(Broad Institute), Anthony Letai(Dana-Farber Cancer Institute), Kay Shigemori(Dana-Farber Cancer Institute), Deborah Plana(Harvard University), Amanda L. Christie(Dana-Farber Cancer Institute), Alexandria Van Scoyk(Dana-Farber Cancer Institute), Justin Cidado(AstraZeneca (United States)), Adam C. Palmer(University of North Carolina at Chapel Hill), J. Paul Secrist(Sage Therapeutics (United States)), Wenchao Wu(State Key Laboratory of Oncology in South China), Jennifer L. Crombie(Dana-Farber Cancer Institute), Lisa Drew(AstraZeneca (United States)), Alwin G. Schuller(AstraZeneca (United States)), Sara Morrow(Dana-Farber Cancer Institute), Elizabeth Brém(UC Irvine Health)
Cited by 63
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
|Proceedings of the National Academy of Sciences|2013|833
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
|The Lancet Oncology|2015|613
The promise of organ and tissue preservation to transform medicine
|Nature Biotechnology|2017|530